布地奈德联合孟鲁司特在小儿咳嗽变异性哮喘治疗中的应用

目的评估布地奈德联合孟鲁司特治疗小儿咳嗽变异性哮喘（CVA）的临床效果及安全性。方法将127例CVA随机分为A组43例、B组42例和C组42例。A组：吸入布地奈德气雾剂200μg,早晚各1次;B组：每晚睡前口服孟鲁司特5 mg 1次;C组：吸入布地奈德气雾剂联合口服孟鲁司特（剂量同A、B组）。观察各组治疗4周后临床效果及不良反应发生情况和治疗8周后肺功能改善情况。随访3个月,观察复发情况。结果治疗4周后C组显效率及总有效率高于A、B组（P〈0.05）,治疗8周后3组肺功能较治疗前明显改善,且C组改善情况优于A、B组,差异均有统计学意义（P〈0.01,P〈0.05）。3组均无严重不良反应。C组复发率显著低于A、B组,差异均有统计学意义（P〈0.05）。结论布地奈德联合孟鲁司特治疗CVA效果满意,且安全性高。

Efficacy and Safety of Budesonide and Montelukast to Treat Children with Cough Variant Asthma

Objective To evaluate the efficacy and safety of Montelukast and inhaled budesonide used in combination or individually in the treatment of children with cough variant asthma（CVA）.Methods 127 CVA patients were randomly divided into group A（n=43）,group B（n=42） and group C（n=42）.For group A,200 μg of inhaled Budesonide was administrated in the morning and evening each day.For group B,oral administration of 5 mg Montelukast was given each night before sleeping.For group C,inhaled Budesonide combined with Montelukast（with the same dosage as group A and group B）.The clinical efficacy and adverse effects were compared after 4 weeks of treatment.The pulmonary function（peek expiratory flow） was evaluated after 8 weeks of treatment.The recurrence rates were compared among those three groups after a 3 month follow-up.Results Group C showed significantly higher efficacyer than group A and group B（P0.05）.The pulmonary function in group C was significantly improved than that of group A and group B（P0.01,P0.05）.There were no serious adverse effects in the three groups.The recurrence rate of group C was significantly lower than that of group A and group B（P0.05）.Conclusion It is safe and efficacious to use Montelukast and Budesonide in combination in the treatment of children with CVA.The efficacy of this combined approach is superior to Montelukast and Budesonide administrated individually.